BioStock published an article on 30 September 2019 about Follicum, which can be read in full below. Follicum’s business strategy is to enter into a partnership, out license or sell their candidates following phase II trials at the latest. With proof-of-concept and top-line-data for FOL-005 firmly within reach during 2020, the company is getting closer […]
What is your background and what have you done before joining Follicum? I have been in the pharmaceutical industry for more than 30 years. After some years in ACO and Pharmacia I joined Recip in 1995 when it started its business. With the exception of one year at Meda in 2008, I have been with […]
This week the yearly event Nordic Life Science Days (NLSDays) took place in Malmö, Sweden. BioStock took the opportunity to talk to Jan Alenfall, the CEO of Follicum, about the status of the company’s projects – hair growth and diabetes. See the interveiw, in English, here. For further information, please contact: Jan Alenfall – CEO, […]
An interview with Follicum’s CEO Jan Alenfall is now published on the company’s website. To access the video, please click here. For further information, please contact: Jan Alenfall – CEO, Follicum AB Telephone: +46 46 19 21 97 Email: info@follicum.com About Follicum AB Follicum is a biotech company focused on the discovery and development of […]
During spring we have reached two important milestones, one in each project. With regards to the hair project we have submitted a patent application for our unique topical formulation of FOL-005, and in the diabetes project we have chosen a candidate. Preparations for a clinical phase II-study with our unique topical formulation of FOL-005 in […]
What is your background and what have you done before joining Follicum? I have more than 35 years of experience in marketing and licensing within the global pharmaceutical industry. Today, I hold the position as Head of Nordic at Tesaro, an American biotech company in oncology, recently acquired by GSK. I have extensive experience from […]
Follicum AB (“Follicum” or “The Company”) today announces that a poster entitled “FOL-005 – modulation of hair growth in clinical studies” will be presented at the 11th World Congress for Hair Research scientific conference in Barcelona, April 24-27, 2019. This conference is one of the most important in the field bringing together the world’s leading […]
On 27 February 2019, Endpoints News published an article about Follicum: “Follicum, a Swedish biotech company born to find a treatment for hair loss, now has diabetes in its crosshairs”. Read the article For further information, please contact: Jan Alenfall – CEO, Follicum AB Telephone: +46 46 19 21 97 Email: info@follicum.com About Follicum AB […]
BioStock has performed a Status Report for Follicum, a peptide-specialized pharmaceutical company active in hair loss and diabetes. The full report is available via this link.
BioStock published an article about Follicum’s topical formulation on 7 February 2019 in Swedish. The article is here translated into English. Follicum develops FOL-005 to stimulate hair growth. The peptide-based candidate has recently undergone a phase IIa-study and the company was able to present positive top-line results during the fall. This summer a topical formulation of […]